Quantum Immunologics is in the process of developing an immunologic treatment for breast cancer that may have positive effects on other types of cancer as well. Phase I and II clinical trials are currently under way in Mobile Alabama. The current trial has a patient base of 27 women with stage IV breast cancer.

The product, currently unnamed, is the result of years of research by staff at the University of South Alabama, College of Medicine and licensed by the South Alabama Medical Science Foundation. The technology centers on an immunogenic, cancer specific protein named OncoFetal Antigen/Immature Laminin Receptor Protein (OFA/iLRP). Several patents are involved in the process, with patents pending also.

Quantum Immunologics is a privately held company. Following all successful trials and approval by the FDA, the company plans to market the treatment, initially in the United States, for the treatment of breast cancer. Studies regarding its use in other types of cancer, as well as a new cancer screening tool are planned.

For additional information regarding QI's current clinical trial, please click here.